G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights

- Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 -

- Achieved $15.8 Million in Net Revenue from Sales of COSELA® (trilaciclib) -